• Anderson PD, D'Aco VJ, Shanahan P, Chapra SC, Buzby ME, Cunningham VL, DuPlessie BM, Hayes EP, Mastrocco FJ, Parke NJ. 2004. Screening analysis of human pharmaceutical compounds in U.S. surface waters. Environ Sci Technol 38:838849.
  • Behr R, Stahler D, Pistell A. 2009. Preliminary characterization of the pharmaceutical content of municipal solid waste landfill leachate from three landfills in Maine. Augusta (ME): Maine Department of Environmental Protection.
  • Castiglioni S, Bagnati R, Fanelli R, Pomati F, Calamari D, Zuccato E. 2006. Removal of pharmaceuticals in sewage treatment plants in Italy. Environ Sci Technol 40:357363.
  • Cunningham VL. 2008. Special characteristics of pharmaceuticals related to environmental fate. In: Kuemmer K, editor. Pharmaceuticals in the environment. 3rd ed. Hidelberg: Springer. p 1324.
  • Cunningham VL, D'Aco VJ, Pfeiffer D, Anderson PD, Buzby ME, Hannah RE, Jahnke J, Parke NJ. 2012. Predicting concentrations of trace organic compounds in municipal wastewater treatment plant sludge and biosolids using the PhATE model. Integr Environ Assess Manag 8:530542.
  • Golder Associates. June 2004. Final report disposal of unused medicines in Subtitle D landfills. Project No: 043-6246. Cherry Hill (NJ).
  • Golet EM, Alder AC, Giger W. 2002. Environmental exposure and risk assessment of fluoroquinolone antibacterial agents in wastewater and river water of the Glatt Valley Watershed, Switzerland. Environ Sci Technol 36:36453651.
  • Gómez MJ, Martínez Bueno MJ, Lacorte S, Fernández-Alba AR, Agüera A. 2007. Pilot survey monitoring pharmaceuticals and related compounds in a sewage treatment plant located on the Mediterranean coast. Chemosphere 66:9931002.
  • IMS Health, Inc. 2001. Reports. IMS Midas Quantum July 2000–August 2001. Collegeville (PA): IMS Health.
  • IMS Health, Inc. 2005. Reports. IMS Midas Quantum July 2004–August 2005. Collegeville (PA): IMS Health.
  • Karthikeyan KG, Meyer MT. 2006. Occurrence of antibiotics in wastewater treatment facilities in Wisconsin, USA. Sci Total Environ 361:196207.
  • Kolpin DW, Furlong ET, Meyer MT, Zaugg SD, Barber LB, Buxton HT. 2002. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999–2000 : A national reconnaissance. Environ Sci Technol 36:12021211.
  • Lindberg RH, Olofsson U, Rendahl P, Johansson MI, Tysklind M, Andersson BAV. 2006. Behavior of fluoroquinolones and trimethoprim during mechanical, chemical, and active sludge treatment of sewage water and digestion of sludge. Environ Sci Technol 40:10421048.
  • O'Leary P, Walsh PW. 1995. Decision maker's guide to solid waste management Vol II. Washington (DC): EPA, Office of Solid Waste.
  • [PDR] Physicians Desk Reference. 2002–2006. Electronic version. Greenswood Village (CO): Thomson Micromedex.
  • Ruggy GH. 1945. A review of problems of sulfonamide chemotherapy. Ohio J Sci 45:115124.
  • 2010. Entry for Trimethoprim. [cited 2011 September.] Available from:
  • Tischler L. 2007. Potential contribution of unused medicines to environmental concentrations of pharmaceuticals. Round Rock, TX: Pharmaceutical Research and Manufacturers of America.
  • [USEPA] US Environmental Protection Agency. 2002. Assessment and recommendations for improving the performance of waste containment systems. Cincinnati (OH): USEPA. EPA/600/R-02/099.
  • [USEPA] US Environmental Protection Agency. 2011. Municipal solid waste generation, recycling, and disposal in the United States: Facts and figures for 2010. [cited 2011 November.] Available from:
  • Vree TB, van der Ven AJAM, Verwey-van Eissen CPWGM, van Ewijik-Beneken EWJ, Kolmer EWJ, Swolfs AEM, van Galen PM, Amatdjais-Groenen H. 2004. Isolation, identification and determination of sulfamethoxazole and its known metabolites in human plasma and urine by high-performance liquid chromatography. J Chromatogr B 658:327340.
  • Williams RT. 2005. Human pharmaceuticals: Assessing the impacts on aquatic ecosystems. Pensacola (FL): SETAC. p 71110.